Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
By LabPulse.com staff writers

July 12, 2019 -- The U.S. Food and Drug Administration (FDA) approved a biologics license application (BLA) on July 9 for Abbott's Alinity s chemiluminescent microparticle immunoassay for detecting antibodies to the hepatitis C virus in human serum and plasma specimens.

The BLA covers the use of hepatitis C virus-encoded antigens for screening individual donors, including volunteer donors, of whole blood and blood components and living donors for the presence of the hepatitis C virus.

The Alinity s is designed to screen blood and plasma more efficiently within a smaller space versus commercially available competitive systems, Abbott noted in a statement on July 11.

WHO expands essential diagnostics list
The World Health Organization (WHO) announced on July 9 that it has updated its Model List of Essential In Vitro Diagnostics with a number of notable...
Kalorama's notable product launches for clinical labs in Q1 2019
What were some of the most notable new product launches for clinical laboratories in the first quarter of 2019? Bruce Carlson of market research firm...

Copyright © 2019 LabPulse.com

Last Updated np 8/2/2019 5:49:22 PM